ReviewJournal of clinical microbiology2025
Emerging technologies for rapid phenotypic antimicrobial susceptibility testing of clinical isolates of bacteria.
Review in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Benchmarking four commercial antimicrobial susceptibility testing systems and disk diffusion to reference broth microdilution in the assessment of gram-negative bacterial isolates.Journal of clinical microbiology · 2026Article
- Rapid microbiological diagnostics for sepsis in critical care: integrating technological advances with antimicrobial stewardship.Acute and critical care · 2026Article
- Point-Counterpoint: The "obsoletogram"-are annual hospital antibiograms still relevant?Journal of clinical microbiology · 2026Article
- Nanomaterial-nucleic acid probe synergy: accelerating rapid pathogen detection and antimicrobial susceptibility testing in bloodstream infections.Folia microbiologica · 2026Review
- [Requirements for the rational use of antibiotics based on antibiotic stewardship].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- End-to-End Timeliness of Blood Culture Diagnostics: A One-Month Observational Study of 5121 Bottles.Antibiotics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Providing timely and accurate antimicrobial susceptibility testing (AST) results is a crucial component of clinical microbiology practice. Commercial rapid AST (RAST) is an emerging and quickly expanding area. These phenotypic RAST systems use various novel methods to monitor bacterial growth and replication in order to shorten the duration of time required for testing. Implementation of RAST has the potential to expedite antimicrobial therapeutic optimization, which can improve patient care. This minireview describes the current state of commercial phenotypic RAST including tests designed to report antimicrobial susceptibilities directly from clinical specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.